BRAF V600 Mutation Analysis
Expected Turnaround Time
14 days
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Clinical Information
Utilized as an independent predictor of colorectal cancer (CRC) patient responsiveness to EGFR inhibitor therapy and to assist with the differentiation of microsatellite instability high (MSI-H) hereditary non-polyposis colon cancer (HNPCC) from sporadic cancer.
Requisition Forms
Specimen Requirements
Specimen Requirements
- Paraffin Embedded Tissue Block: FFPE Block, 10% NBF Fixed
- Paraffin Embedded Tissue Slides: 5 slides or scrolls (minimum 5-10 μM), 10% NBF Fixed
Specimen Stability
Indefinite
Storage Requirements
15°C to 25°C
Shipping Conditions
Ambient
Shipping Recommendations
AMBIENT, Use a refrigerated (NOT FROZEN) gel pack in the shipment to protect from extreme temperatures. Separate gel pack from specimen.
Specimen Rejection Criteria
Improper specimen labeling; Insufficient tissue; Insufficient tumor burden; Insufficient DNA isolated
Test Details
Synonyms
EGFR inhibitor response
Keywords
Companion Diagnostics, Molecular Diagnostics, Oncology, Mutation Analysis, DNA Sequencing, Gastrointestinal Cancer, Melanoma, Head and Neck, or Anal Cancer, Lung Cancer, Genomics, Next Generation Sequencing
Test Method
Next Generation Sequencing (NGS)
Methodology Category
Molecular
Regulatory Status
RUO
Special Considerations
- FFPE block preferred; unbaked slides acceptable.
- Include a surgical pathology report with the sample
Associations
Colorectal cancer (CRC), hereditary non-polyposis colon cancer (HNPCC), metastatic melanoma, papillary thyroid carcinoma; BRAF Mutation in Melanoma